Physician profile
Savitha Shivananda
NPI 1104831684
$19,517.97
in general payments reported to CMS, 2019-2025
53 companies · $3,104 in 2025
The $3,104 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,594 · 2020: $1,659 · 2021: $2,869 · 2022: $2,666 · 2023: $3,689 · 2024: $2,938 · 2025: $3,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,662 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,662.03 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,578.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,706.01 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Dexcom, INC. | $1,440.76 | 2021-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $1,385.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $1,160.35 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $1,066.05 | 2019-2025 | |
| Abbvie INC. | $1,065.69 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Abbott Laboratories | $846.59 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $839.70 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $810.51 | 2019-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $717.72 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $714.36 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $620.53 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $475.68 | 2019-2025 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $454.14 | 2019-2024 | Verquvo, Belsomra |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savitha Shivananda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.